FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2900261005> ?p ?o ?g. }

• W2900261005 endingPage "e0207387" @default.
• W2900261005 startingPage "e0207387" @default.
• W2900261005 abstract "Coagulation activation and venous thromboembolism (VTE) are hallmarks of cancer; however, there is an unmet need of improved biomarkers for individualized anticoagulant treatment. The present sub-study of the RASTEN trial was designed to explore the role of coagulation biomarkers in predicting VTE risk and outcome in a homogenous cancer patient population. RASTEN is a multicenter, randomized phase-3 trial investigating the survival effect of low molecular weight heparin enoxaparin when added to standard treatment in newly diagnosed small cell lung cancer (SCLC) patients. Plasma collected at baseline, during treatment, and at follow-up was used in this ad hoc sub-study (N = 242). Systemic coagulation was assessed using four assays reflecting various facets of the coagulation system: Total tissue factor (TF); extracellular vesicle associated TF (EV-TF); procoagulant phospholipids (PPL); and thrombin generation (TG). We found small variations of biomarker levels between baseline, during treatment and at follow-up, and appeared independent on low molecular weight heparin treatment. Overall, none of the measured biomarkers at any time-point did significantly associate with VTE incidence, although increased total TF at baseline showed significant association in control patients not receiving low molecular weight heparin (P = 0.03). Increased TG-Peak was significantly associated with decreased overall survival (OS; P = 0.03), especially in patients with extensive disease. Low baseline EV-TF predicted a worse survival in the low molecular weight heparin as compared with the control group (HR 1.42; 95% CI 1.04-1.95; P = 0.03; P for interaction = 0.12). We conclude that the value of the analyzed coagulation biomarkers for the prediction of VTE risk was very limited in SCLC patients. The associations between TG-Peak and EV-TF with patient survival and response to low molecular weight heparin therapy, respectively, warrant further studies on the role of coagulation activation in SCLC aggressiveness." @default.
• W2900261005 created "2018-11-16" @default.
• W2900261005 creator A5006228359 @default.
• W2900261005 creator A5009891370 @default.
• W2900261005 creator A5017127306 @default.
• W2900261005 creator A5025672336 @default.
• W2900261005 creator A5029670516 @default.
• W2900261005 creator A5044764887 @default.
• W2900261005 creator A5050363054 @default.
• W2900261005 creator A5061921179 @default.
• W2900261005 creator A5062287073 @default.
• W2900261005 creator A5075147644 @default.
• W2900261005 creator A5075629445 @default.
• W2900261005 creator A5085102712 @default.
• W2900261005 date "2018-11-09" @default.
• W2900261005 modified "2023-10-11" @default.
• W2900261005 title "Coagulation biomarkers and prediction of venous thromboembolism and survival in small cell lung cancer: A sub-study of RASTEN - A randomized trial with low molecular weight heparin" @default.
• W2900261005 cites W1517180241 @default.
• W2900261005 cites W1966329335 @default.
• W2900261005 cites W1979522770 @default.
• W2900261005 cites W1996544895 @default.
• W2900261005 cites W2007086823 @default.
• W2900261005 cites W2008349434 @default.
• W2900261005 cites W2010084870 @default.
• W2900261005 cites W2013425855 @default.
• W2900261005 cites W2019336592 @default.
• W2900261005 cites W2023699475 @default.
• W2900261005 cites W2024745748 @default.
• W2900261005 cites W2026410953 @default.
• W2900261005 cites W2033150840 @default.
• W2900261005 cites W2044540189 @default.
• W2900261005 cites W2044979792 @default.
• W2900261005 cites W2063343394 @default.
• W2900261005 cites W2092583562 @default.
• W2900261005 cites W2108446523 @default.
• W2900261005 cites W2116944485 @default.
• W2900261005 cites W2119531959 @default.
• W2900261005 cites W2119768870 @default.
• W2900261005 cites W2125102123 @default.
• W2900261005 cites W2143936626 @default.
• W2900261005 cites W2150238019 @default.
• W2900261005 cites W2154344198 @default.
• W2900261005 cites W2158828810 @default.
• W2900261005 cites W2177587731 @default.
• W2900261005 cites W2196970594 @default.
• W2900261005 cites W2257098687 @default.
• W2900261005 cites W2327529158 @default.
• W2900261005 cites W2331374181 @default.
• W2900261005 cites W2464221347 @default.
• W2900261005 cites W2502322396 @default.
• W2900261005 cites W2561518205 @default.
• W2900261005 cites W2612016081 @default.
• W2900261005 cites W2767140416 @default.
• W2900261005 cites W2786262376 @default.
• W2900261005 cites W4253278951 @default.
• W2900261005 cites W4385969812 @default.
• W2900261005 doi "https://doi.org/10.1371/journal.pone.0207387" @default.
• W2900261005 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6226210" @default.
• W2900261005 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30412630" @default.
• W2900261005 hasPublicationYear "2018" @default.
• W2900261005 type Work @default.
• W2900261005 sameAs 2900261005 @default.
• W2900261005 citedByCount "34" @default.
• W2900261005 countsByYear W29002610052019 @default.
• W2900261005 countsByYear W29002610052020 @default.
• W2900261005 countsByYear W29002610052021 @default.
• W2900261005 countsByYear W29002610052022 @default.
• W2900261005 countsByYear W29002610052023 @default.
• W2900261005 crossrefType "journal-article" @default.
• W2900261005 hasAuthorship W2900261005A5006228359 @default.
• W2900261005 hasAuthorship W2900261005A5009891370 @default.
• W2900261005 hasAuthorship W2900261005A5017127306 @default.
• W2900261005 hasAuthorship W2900261005A5025672336 @default.
• W2900261005 hasAuthorship W2900261005A5029670516 @default.
• W2900261005 hasAuthorship W2900261005A5044764887 @default.
• W2900261005 hasAuthorship W2900261005A5050363054 @default.
• W2900261005 hasAuthorship W2900261005A5061921179 @default.
• W2900261005 hasAuthorship W2900261005A5062287073 @default.
• W2900261005 hasAuthorship W2900261005A5075147644 @default.
• W2900261005 hasAuthorship W2900261005A5075629445 @default.
• W2900261005 hasAuthorship W2900261005A5085102712 @default.
• W2900261005 hasBestOaLocation W29002610051 @default.
• W2900261005 hasConcept C121608353 @default.
• W2900261005 hasConcept C126322002 @default.
• W2900261005 hasConcept C143998085 @default.
• W2900261005 hasConcept C168563851 @default.
• W2900261005 hasConcept C186738567 @default.
• W2900261005 hasConcept C2776256026 @default.
• W2900261005 hasConcept C2776884760 @default.
• W2900261005 hasConcept C2777557582 @default.
• W2900261005 hasConcept C2778382381 @default.
• W2900261005 hasConcept C2781197716 @default.
• W2900261005 hasConcept C2908647359 @default.
• W2900261005 hasConcept C55493867 @default.
• W2900261005 hasConcept C71924100 @default.
• W2900261005 hasConcept C86803240 @default.
• W2900261005 hasConcept C90924648 @default.
• W2900261005 hasConcept C99454951 @default.

• next